rian.ie - Results

A A A

Current Search:	'Biochemistry' in all fields;

Displaying Results 1 - 25 of 301 on page 1 of 13

Mark

Interleukin-1 signal transduction: increased GTP binding and hydrolysis in membranes of a murine thymoma line (EL4). (1990)

O'NEILL, LUKE ANTHONY JOHN

Mark

Interleukin 1 induces NF-kappa B through its type I but not its type II receptor in lymphocytes. (1992)

O'NEILL, LUKE ANTHONY JOHN

Mark

Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78 (1995)

O'NEILL, LUKE ANTHONY JOHN

Mark

Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit. (1995)

O'NEILL, LUKE ANTHONY JOHN

Mark

Daunorubicin activates NFkappaB and induces kappaB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells (1997)

O'NEILL, LUKE ANTHONY JOHN

Mark

Ceramide activates NFkappaB by inducing the processing of p105 (1998)

O'NEILL, LUKE ANTHONY JOHN

Mark

Rac1 regulates interleukin 1-induced nuclear factor kappaB activation in an inhibitory protein kappaBalpha-independent manner by enhancing the ability of the p65 subunit to transactivate gene expression (2000)

O'NEILL, LUKE ANTHONY JOHN

Mark

Divergent roles for Ras and Rap in the activation of p38 mitogen-activated protein kinase by interleukin-1 (2000)

O'NEILL, LUKE ANTHONY JOHN; PALSSON, EVA

Mark

Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells (2000)

O'NEILL, LUKE ANTHONY JOHN

Mark

Internalin B activates nuclear factor-kappa B via Ras, phosphoinositide 3-kinase, and Akt (2001)

O'NEILL, LUKE ANTHONY JOHN

Mark

Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1 (2002)

O'NEILL, LUKE ANTHONY JOHN

Mark

Bruton's tyrosine kinase is a Toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor kappaB activation by Toll-like receptor 4 (2003)

O'NEILL, LUKE ANTHONY JOHN

Mark

Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR3 requires the p65 subunit of NF-kappa (2003)

O'NEILL, LUKE ANTHONY JOHN

Mark

The murine IRAK2 gene encodes four alternatively spliced isoforms, two of which are inhibitory (2004)

O'NEILL, LUKE ANTHONY JOHN

Mark

Crystal structure of the Toll/interleukin-1 receptor domain of human IL-1RAPL (2004)

O'NEILL, LUKE ANTHONY JOHN

Mark

Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4 (2004)

O'NEILL, LUKE ANTHONY JOHN

Mark

Human tribbles, a protein family controlling mitogen-activated protein kinase cascades (2004)

O'NEILL, LUKE ANTHONY JOHN

Mark

Schlafen-1 causes a cell cycle arrest by inhibiting induction of cyclin D1 (2005)

O'NEILL, LUKE ANTHONY JOHN

Mark

IkappaB kinase epsilon interacts with p52 and promotes transactivation via p65 (2006)

O'NEILL, LUKE ANTHONY JOHN

Mark

Mass Spectrometric Analysis of the Endogenous Type I Interleukin-1 (IL-1) Receptor Signaling Complex Formed after IL-1 Binding Identifies IL-1RAcP, MyD88, and IRAK-4 as the Stable Components (2007)

O'NEILL, LUKE ANTHONY JOHN

Mark

Tyrosine phosphorylation of MyD88 adapter-like (Mal) is critical for signal transduction and blocked in endotoxin tolerance (2008)

O'NEILL, LUKE ANTHONY JOHN

Mark

Queuosine formation in eukaryotic tRNA occurs via a mitochondrial localized heteromeric transglycoslase. (2009)

KELLY, VINCENT PATRICK

Mark

Platelet factor 4 impairs the anticoagulant activity of activated protein C. (2009)

HARMON, SHONA; PRESTON, ROGER; JOHNSON, JENNIFER; O'DONNELL, JAMES; NI AINLE, FION...

Mark

Characterization of two protein disulphide iosmerases from the endocytic pathway of Trypanosoma brucei (2005)

NOLAN, DEREK

Mark

Study of the Efficacy, Biodistribution, and Safety Profile of Therapeutic Gutless Adenovirus Vectors as a Prelude to a Phase I Clinical Trial for Glioblastoma (2010)

Muhammad, AKM Ghulam; Puntel, Mariana; Candolfi, Marianela; Salem, A; Yagiz, Kader; Far...

Study of the Efficacy, Biodistribution, and Safety Profile of Therapeutic Gutless Adenovirus Vectors as a Prelude to a Phase I Clinical Trial for Glioblastoma (2010)

Muhammad, AKM Ghulam; Puntel, Mariana; Candolfi, Marianela; Salem, A; Yagiz, Kader; Farrokhi, C; Kroeger, Kurt M; Xiong, Weidong; Curtin, James; Liu, Chunyan; Lawrence, K; Bondale, Niyati; Lerner, Jonathan; Baker, G; Foulad, David; Pechnick, Robert; Palmer, Donna; Ng, Philip; Lowenstein, Pedro; Castro, Maria

Abstract:

Glioblastoma multiforme (GBM) is the most common and most aggressive primary brain tumor in humans. Systemic immunity against gene therapy vectors has been shown to hamper therapeutic efficacy; however, helper-dependent high-capacity adenovirus (HC-Ad) vectors elicit sustained transgene expression, even in the presence of systemic anti-adenoviral immunity. We engineered HC-Ads encoding the conditional cytotoxic herpes simplex type 1 thymidine kinase (TK) and the immunostimulatory cytokine fms-like tyrosine kinase ligand 3 (Flt3L). Flt3L expression is under the control of the regulatable Tet-ON system. In anticipation of a phase I clinical trial for GBM, we assessed the therapeutic efficacy, biodistribution, and clinical and neurotoxicity with escalating doses of HC-Ad-TetOn-Flt3L + HC-Ad-TK in rats. Intratumoral administration of these therapeutic HC-Ads in rats bearing large intracranial GBMs led to long-term survival in ~70% of the animals and development of antiglioma immunologic...

http://arrow.dit.ie/scschbioart/53

Displaying Results 1 - 25 of 301 on page 1 of 13

Legal Information | Copyright Information

built by Enovation Solutions

Search using:

Optionally, filter by:

in
in
in

From To